Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.

Pharmacogenetics and genomics - 1 Aug 2013

Tavira Beatriz, Coto Eliecer, Diaz-Corte Carmen, Alvarez Victoria, López-Larrea Carlos, Ortega Francisco

Abstract excerpt

The CYP3A5*3 and CYP3A4*1B alleles have been related with tacrolimus (Tac) dose requirements. The rare CYP3A4*22 variant has also been associated with a significantly lower Tac dose. We genotyped the three single-nucleotide polymorphisms in 206 kidney-transplanted patients who received Tac as the primary immunosuppressor. CYP3A5*1 and CYP3A4*1B allele carriers received a significantly higher Tac dose (P<0.01)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Polymorphism, Single Nucleotide

Share to Renal Transplantation Outcomes and Treatments

Share to Tacrolimus

Source

Identifiers

PMID: 23778326
DOI: 10.1097/FPC.0b013e3283636856

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients.PMID 23778326Read ↗

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.Semantic proximity Read ↗

Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.Semantic proximity Read ↗

Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.Semantic proximity Read ↗

Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.Semantic proximity Read ↗

Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.Semantic proximity Read ↗

CYP3A4*1B but Not CYP3A5*3 as Determinant of Long-Term Tacrolimus Dose Requirements in Spanish Solid Organ Transplant Patients.Semantic proximity Read ↗

The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.Semantic proximity Read ↗

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant CenterSemantic proximity Read ↗

CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.Semantic proximity Read ↗

Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.Semantic proximity Read ↗

The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Semantic proximity Read ↗

Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.